Company profile: Genkyotex
1.1 - Company Overview
Company description
- Provider of innovative drugs and platform technology that block NOX enzymes producing oxygen radicals to treat oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy. Offerings include setanaxib and a NOX inhibitor platform.
Products and services
- Innovative NOX-blocking drugs: Genkyotex develops enzyme-specific therapeutics to block NOX enzymes that produce oxygen radicals, enabling treatment of oxygen-radical mediated acute and chronic diseases with improved specificity, safety, and efficacy
- NOX inhibitor platform: A NOX-focused platform develops inhibitors targeting NOX enzymes that generate oxygen radicals, delivering compounds with improved specificity, safety, and efficacy compared to existing antioxidant therapy
- Setanaxib: A NOX-targeted drug engineered to block NOX enzymes producing oxygen radicals, aiming to treat oxygen-radical mediated acute and chronic diseases with superior specificity, safety, and efficacy versus antioxidant therapies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Genkyotex
Endo
HQ: Ireland
Website
- Description: Provider of branded and generic pharmaceuticals for patient care, offering affordable, high-quality generics and treatments for unmet pelvic health needs; supplies products tailored to Canadian and emerging markets, and engages in public policy advocacy to enhance patient access, alongside a UK tax strategy focused on compliance and responsible planning.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endo company profile →
Covagen
HQ: Switzerland
Website
- Description: Provider of bispecific FynomAbs by fusing human Fynomer binding proteins to antibodies, creating protein-based therapeutics with novel modes of action and enhanced efficacy for the treatment of inflammatory diseases and cancer; ability to fuse Fynomers to multiple antibody sites enables tailored architectures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Covagen company profile →
Farmalider
HQ: Spain
Website
- Description: Provider of development, registration, licensing and manufacturing of generic pharmaceuticals, with two plants producing prescription, OTC and dietary supplement products in liquid, granulated and solid oral forms. Specializes in pain management, leading in ibuprofen and paracetamol in Spain. Services include formulation R&D, clinical trial batches, registration documentation, pharmacovigilance, and supply of generics in growing European markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Farmalider company profile →
Cyclo Therapeutics
HQ: United States
Website
- Description: Provider of cyclodextrin-based therapeutics, including Trappsol® Cyclo™, a proprietary hydroxypropyl beta cyclodextrin formulation in clinical trials for Niemann-Pick Disease Type C1 and in a Phase 2b trial for early Alzheimer’s disease, leveraging data from an Expanded Access program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cyclo Therapeutics company profile →
Lilly
HQ: United States
Website
- Description: Provider of medicines for diabetes, cancer, immunology, and other major health areas, including insulin products with affordability initiatives ($35 or less/month); Efsitora for type 2 diabetes via autoinjector; EBGLYSS for moderate-to-severe atopic dermatitis; Jaypirca for relapsed/refractory MCL and CLL/SLL; Zepbound (tirzepatide) for obesity; Verzenio for HR+, HER2- early breast cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lilly company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Genkyotex
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Genkyotex
2.2 - Growth funds investing in similar companies to Genkyotex
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Genkyotex
4.2 - Public trading comparable groups for Genkyotex
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →